Research programme: kinase inhibitor drug conjugates - Tarveda Therapeutics
Latest Information Update: 28 Aug 2025
At a glance
- Originator Synta Pharmaceuticals
- Developer Madrigal Pharmaceuticals
- Class Antineoplastics; Drug conjugates; Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Aug 2025 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 21 Aug 2023 Preclinical development is ongoing in USA (SciClone Pharmaceuticals, Pipeline August 2023)
- 28 Mar 2022 No recent reports of development identified for preclinical development in Solid-tumours in USA